[HTML][HTML] APOBEC3B spreads somatic mutations in breast cancer genome
GI Forte - Translational Cancer Research, 2013 - tcr.amegroups.org
During our genomic era, the landscape of somatic mutations has been largely studied in
several types of carcinomas, producing evidences that the mutation spectra can be different …
several types of carcinomas, producing evidences that the mutation spectra can be different …
[图书][B] Hepatocyte Differentiation and Hepatocellular Carcinoma: Rationale for p53 Independent Therapy
FO Enane - 2017 - search.proquest.com
The era of genomic revolution illustrated that cancer is a genetic disease where alterations
impair specific cellular pathways. For instance, cancer cells frequently physically remove cell …
impair specific cellular pathways. For instance, cancer cells frequently physically remove cell …
DNA demethylation agents in clinical medicine
M Szyf - Handbook of Epigenetics, 2017 - Elsevier
DNA methylation is a fundamental epigenetic mechanism that is involved in long-term
programming of gene expression and in determining cell fate by regulating cell-specific …
programming of gene expression and in determining cell fate by regulating cell-specific …
[PDF][PDF] OFFICIAL TITLE: Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, alone or in combination with Oral Decitabine/Tetrahydrouridine as Second …
N Pennell, DS Schrump, J Stevenson, M Shapiro… - classic.clinicaltrials.gov
1.1 Background of Refractory Non-small cell lung cancer 1.2 Rationale for the use of
Tetrahydrouridine-Decitabine in lung cancer 1.3 Mechanisms of immune-resistance in lung …
Tetrahydrouridine-Decitabine in lung cancer 1.3 Mechanisms of immune-resistance in lung …
Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network
X Gu, R Tohme, B Tomlinson, M Hasipek, L Durkin… - bioRxiv, 2020 - biorxiv.org
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …
Platelet-cancer Crosstalk: Mechanisms and Therapeutic Implications
O Elaskalani - 2019 - espace.curtin.edu.au
Platelets are small anucleate blood cells that are central to primary haemostasis. However,
platelets are also implicated in cancer pathogenesis. This thesis showed that cancer cells …
platelets are also implicated in cancer pathogenesis. This thesis showed that cancer cells …
Rôle de la cytidine désaminase dans le contrôle du métabolisme énergétique tumoral pancréatique
A Frances - 2019 - theses.hal.science
Le cancer du pancréas est un des cancers aux pronostics les plus sombres, avec une survie
à 5 ans inférieure à 10%. Associé à une incidence en hausse dans les pays développés, et …
à 5 ans inférieure à 10%. Associé à une incidence en hausse dans les pays développés, et …
Synergistic activity of parthenolide and cytarabine in acute promyelocytic leukemia HL-60 cell line
M Papież, W Krzyściak - Journal of Unexplored Medical Data, 2018 - ruj.uj.edu.pl
Aim: Investigation of the influence of parthenolide (PTL) on cytarabine (Ara-C) action in an
acute promyelocytic leukemia HL-60 cell line and the role of oxidative stress in its action …
acute promyelocytic leukemia HL-60 cell line and the role of oxidative stress in its action …
Development of chemical probes for intracellular nucleotide delivery, profiling of the metabolic fate (s) of nucleoside monoester phosphoramidates, and a nucleotide …
A Okon - 2018 - conservancy.umn.edu
Significant progress has been made towards the development of phosphate prodrugs for
intracellular delivery of monophosphates. Such efforts led to the successful application of the …
intracellular delivery of monophosphates. Such efforts led to the successful application of the …
Development of PEG-sheddable pH-sensitive liposomes for cytoplasmic drug delivery to pancreatic cancer
M Kanamala - 2018 - researchspace.auckland.ac.nz
Background: Conventional chemotherapy is still the main stay treatment for cancer, but its
efficacy is limited by its nonspecific drug distribution and lack of selectivity. Compared to …
efficacy is limited by its nonspecific drug distribution and lack of selectivity. Compared to …